LILLY-F1D-CA-P022

Study Sponsor: Lilly

Study Title

Olanzapine versus Haloperidol and Risperidone in the Treatment of Schizophrenia

Medicine or Vaccine (generic name)

Olanzapine

Sponsor Identification Number

F1D-CA-P022

Trial Registry Identification Number(#'s)

Not available

Medical Condition

Schizophrenia

Phase

Phase 4

Link to study details on the Lilly Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Not available

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

August 2016